Causes for the high mortality from asthma in New Zealand were investigated by comparing deaths from asthma in caucasian subjects aged 15-64 in New Zealand with those from asthma in the same age group in two regions in England. There were no significant differences in the accuracy of death certification. The verified asthma mortality in New Zealand (4-2/100 000) was over twice that in England. Many characteristics of patients and management, including poor compliance with treatment and deficiencies in long term and emergency care, were qualitatively similar in the two countries. New Zealand had an apparently higher rate of non-preventable deaths from asthma, suggesting a greater severity of asthma in New Zealand. In both countries, however, most deaths were associated with poor assessment, underestimation of severity and inappropriate treatment (overreliance on bronchodilators and underuse of systemic corticosteroids), and delays in obtaining help. A greater frequency of some of these deficiencies in management remains a possible additional explanation for part of the excess mortality in New Zealand.
Introduction
There is now no doubt that New Zealand experienced an increase in asthma mortality in the late 1970s, especially in the 5-34 year age group, whose mortality from asthma rose abruptly from 1977 . ' Hospital admission rates for asthma increased,2 and while sales of antiasthma drugs also increased in the United Kingdom and Australia between 1975 and 1981, sales per head were highest in New Zealand.3 There was concern that changing patterns of drug treatment, particularly the combination of oral theophylline with f3 sympathomimetic drugs4 and the use of home nebulisers for administration of high doses of 3 
Methods
The Asthma Task Force of the Medical Research Council of New Zealand undertook a two year national review of all deaths in people usually resident in New Zealand who died between 1 August 1981 and 31 July 1983 and for whom part I of the death certificate or the coroner's report contained the word "asthma," "asthmatic," or "asthmaticus. Cases were identified by reviews of death certificates at local offices of registrars of births, deaths, and marriages and at the National Registry of Births, Deaths, and Marriages. After separate interviews with a close relative or friend and the general practitioner by a trained nurse interviewer, review of hospital records, and study of necropsy findings where available a panel of respiratory physicians determined whether the patient had suffered from asthma and whether the patient had died from asthma or its complications or treatment.8 If so, the panel reviewed the characteristics of the patient, the long term care, particularly over the year before death, the circumstances of the fatal episode, and the possibilities for intervention which might have prevented a fatal outcome.
After completion of data collection two of us had discussions with a member of the asthma mortality subcommittee of the British Thoracic Association, and subsequently one reviewed 15 representative New Zealand cases with two members of the subcommittee, who did not know the assessments of the New Zealand panel, to determine comparability of judgments regarding adequacy of management and preventability of death.
Results

DEMOGRAPHIC DATA
The verified mortality from asthma in 15-64 year olds of all races in New Zealand was 5-6/100000 compared with 1 84/100000 in England.6 As reported, death rates for asthma in the Maori and Pacific Island Polynesian populations were respectively 5-5 (p<001) and 2-8 (p<005) times higher than the rate for caucasians these higher rates accounted for 36% of the "excess" of the total New Zealand asthma mortality. The The age and sex distribution of the subjects who died was similar in the two countries (table II) . There were no significant differences in the ages at onset or durations of asthma; in both countries about 80% of patients had had asthma for over 10 years. One third of patients dying of asthma in England had been free of symptoms for periods of three months or more in the year before death, but this was rare in New Zealand patients, only 6% of whom had mild asthma not requiring emergency visits to a general practitioner or hospital in the year before death. In England 39% of patients had had previous, sudden severe attacks, while in New Zealand 29% of patients had had life threatening episodes of asthma resulting in altered consciousness or documented hypercapnia. In one in 10 fatal cases in New 
DRUG TREATMENT
Comparatively more New Zealand patients with fatal asthma had used theophylline, inhalational corticosteroid, and nebulised bronchodilator, but systemic corticosteroids were less frequently used than in England (table IV) . Treatment as prescribed by the general practitioner comprised both bronchodilator and anti-inflammatory agents in 49% of cases, but in many of these patients the dosages may have been inadequate, as lung function was not assessed. A home nebuliser was used by a quarter of the New Zealand patients for occasional or regular administration of a P sympathomimetic, but many patients, including more than half of those with previous life threatening attacks, did not have access to oxygen or to a nebuliser. In England no patient dying of asthma had a home nebuliser. In both countries few relatives seemed to have a clear grasp of how to identify and manage severe attacks ("crisis plan").
CIRCUMSTANCES OF FATAL ATTACK
In both New Zealand and England the duration of the final attack varied between minutes and several days; in a quarter of cases the patient died in less than one hour from the apparent onset of the attack (table V). In New Zealand 31% of patients were known to have died within three hours of the apparent onset; a further 19% probably died in under three hours, but as they were found dead the time of death was less certain. Similar proportions of patients died at weekends and at night in the two countries. Fewer than half of all patients called their general practitioner or a deputy medical service. Only one fifth of patients in New Zealand called an ambulance compared with 38% in England; possibly as a result 14% died en route to medical care, mostly in private cars. Important delays in seeking medical help were evident in 37% of New Zealand cases, whereas in England 54% of patients were considered to have delayed or failed to call help.
We found no evidence in Caucasian New Zealand patients of excess theophylline usage in the fatal attack, and only five patients appeared to have used a 13 agonist in doses exceeding those used regularly in hospital inpatients with acute severe asthma-namely, nebulisation of salbutamol or fenoterol 2 5-5 0 mg every two hours. Cardiac arrhythmia due to drugs in the presence of hypoxia might explain the very few extremely sudden deaths, but we have no evidence for or against this hypothesis. As in England, however, there was evidence of underusage of systemic corticosteroids, both during the period of gradual deterioration leading to the final attack and at the time of medical intervention (46% of those treated during the attack were given little or no corticosteroid). In New Zealand 50 patients (34%) had had a recent attack which was poorly assessed or poorly treated and 18 (12%) had recently stopped or rapidly reduced their dose of oral steroids. Four patients were taking 13 adrenergic blocking drugs, which in three contributed directly to death. There were no deaths after ingestion of aspirin or non-steroidal anti-inflammatory drugs. Twenty patients used antianxiety or antipsychotic drugs. Sedatives were given in only one of the fatal asthmatic attacks studied. The national asthma mortality study has shown that the higher reported rates in New Zealand compared with England were not due to a greater proportion oferrors ofcertification or coding.89 The methods of case review in each country excluded any effect from the introduction of the ninth revision of the International Classification of Diseases in 1979." The verified mortality of 4-2/100000 New Zealand Caucasians aged 15-64 confirmed the New Zealand mortality from asthma in 1981-3 to be more than twice that of England in 1979. Had the study by the British Thoracic Association been contemporaneous with the New Zealand study this difference might have been slightly less, as asthma mortality is increasing slowly in England and Wales,'2 but this change with time is small compared with the substantial difference between the two countries.
If data from the two regions studied in England are applicable nationally, and if the judgments made about whether or not deaths were preventable were comparable between countries, then the rate for "unavoidable" mortality from asthma was considerably greater in New Zealand than in the United Kingdom (table VI). Without both groups undertaking an independent review of all cases studied in both countries we cannot be certain that the same judgments would be made on all cases, but the two members of the British Thoracic Association's subcommittee who reviewed 15 representative New Zealand cases without knowledge of the New Zealand panel's assessment made identical judgments on which deaths were associated with "avoidable" factors. These factors included underassessment of severity of chronic asthma resulting in inadequate long term care, poor patient compliance with treatment (often BRITISH MEDICAL JOURNAL VOLUME 293 22 NovEMBER 1986 1345 associated with psychological problems and smoking), poor use of primary medical care, delay in calling for help in circumstances of increasing asthma, and underassessment of severity and inappropriate treatment of the acute attack.
Identified inadequacies in the long term management of patients with severe asthma in New Zealand were similar to those reported in England.61314 Probably many ofthe patients who died ofasthma had poorly recognised chronic airflow limitation which could have been reversed or improved with more aggressive treatment, including oral corticosteroids.
Reluctance to initiate or increase steroid treatment for acute attacks and failure to monitor response to such treatment when it was used were common. An arbitrary five or seven day course of prednisone without subsequent clinical and functional review of the patient is dangerous: it may fail fully to reverse the airflow obstruction and may leave the patient susceptible to a further exacerbation of asthma as treatment is withdrawn. Instead, prednisone 30-60 mg daily should be maintained for up to two weeks, until the peak expiratory flow returns to normal (or to the patient's known maximum) and there is minimal diurnal variation. 15 When the prednisone dose is reduced peak flow measurements should be continued as well as clinical review and dose reduction halted if there is deterioration. Failure to initiate or increase inhalational steroids during withdrawal of oral steroids was another common error in management of the fatal cases in New Zealand.
The subcommittee of the British Thoracic Association recommended nebulised bronchodilator treatment as probably the best emergency treatment for acute asthma.' In that study no patient had used a home nebuliser during the fatal attack. In New Zealand, perhaps because the study was undertaken two years later, and possibly because of a greater severity of asthma, nebulisers were prescribed for a quarter of those who died. In at least 12 instances over-reliance on a nebuliser led to a delay in seeking medical help or initiating other action.'0 Grant was concerned about the high prevalence of use of nebulisers in New Zealand, particularly without peak flow monitoring or availability of oxygen. 5 We emphasise the need for careful patient education in the use of nebulisers and the need for peak flow monitoring and an effective crisis plan for all patients requiring this form of treatment. As reported elsewhere, however, we believe that misuse ofnebulisers at home contributed only slightly to asthma mortality in New Zealad.'°W e found no direct evidence for bronchodilator drug toxicity, with no documented arrhythmias in patients admitted to hospital and no excessive theophylline doses or raised serum theophylline concentrations. Nor did we find that emergency management, when given, was hampered by the inability to use parenteral aminophylline in patients taking oral sustained release theophylline, which was prescribed more frequently in New Zealand than in England. The greatest increase in mortality in younger patients occurred three years before the abrupt increase in sales of antiasthma drugs,3 making an association between increased treatment and mortality unlikely. While The fall in asthma mortality in New Zealand in 1983, when our study ended, may have reflected an increased awareness of asthma mortality both within the profession and among the public with consequent improved management. Nevertheless, we remain concerned about the higher mortality compared with other countries. This is not an artefact ofcertification and may not be fully explained by the identifiable defects of management. The apparently higher rate of"unavoidable" deaths in New Zealand suggests that there are other factors which must be considered, including a change in severity of asthma. The anecdotal experience of immigrant physicians treating asthma in different countries,'6 the increased prevalence and severity ofasthma in Tokelauan immigrants to New Zealand,"7 the sharp increase in use of antiasthma drugs in New Zealand,3 and this comparison of the New Zealand and English studies of asthma mortality suggest that as yet unknown environmental factors may have had an adverse effect on asthma mortality in New Zealand. On the other hand, this study does provide evidence for quantitative differences between New Zealand and England in some aspects of management of asthma, including drug use and patient willingness to present for medical care and review.
We must leave open the-possibility that these differences might account for at least part of the excess New Zealand mortality from asthma. 
